Valneva SE
VALN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001836564
No open-market purchases or sales by Valneva SE insiders were filed in the last 90 days; 20 institutions reported holding it in 13F filings for Q2 2026, worth $19.8M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Valneva SE changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 14 | 18 | +4 |
| Shares | 674.5K | 4.52M | +3.85M (+570.3%) |
| Value | $4.53M | $25.6M | +$21.1M (+465.6%) |
New holders (4)
Institutions that held Valneva SE at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Novo Holdings A/S | 2,375,000 | $13.5M | 0.95% |
| Frazier Life Sciences Management, L.P. | 1,458,333 | $8.24M | 0.33% |
| EverSource Wealth Advisors, LLC | 93 | $527 | 0.00% |
| Raymond James Financial Inc | 41 | $232 | 0.00% |
Sold out (0)
Institutions that held Valneva SE at the end of Q1 2025 and filed for Q2 2025 without it.
None.